Marc S. Ernstoff
Impact in
- Oncology top 0.05%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cutaneous Melanoma Detection and Management
- Immunology top 0.2%
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- Immune cells in cancer
Papers in
- Oncology 152
- Cancer Immunotherapy and Biomarkers 77
- CAR-T cell therapy research 43
- Cutaneous Melanoma Detection and Management 27
- Immunology 82
- Immunotherapy and Immune Responses 65
- Immune Cell Function and Interaction 22
- Co-authors
- John M. Kirkwood (49 shared papers)Ronald H. Blum (4 shared papers)Thomas J. Smith (3 shared papers)Joseph G. Ibrahim (4 shared papers)Vernon K. Sondak (4 shared papers)Uma Rao (3 shared papers)Michael B. Atkins (26 shared papers)Kim Margolin (27 shared papers)
- Journals
- Journal of Clinical Oncology (79 papers)Journal for ImmunoTherapy of Cancer (12 papers)Journal of Immunotherapy (12 papers)Clinical Cancer Research (11 papers)Cancer (9 papers)
- Partner nations
- United StatesUnited KingdomCanada
In The Last Decade
Marc S. Ernstoff
294 papers receiving 15.6k citations
Marc S. Ernstoff's Hit Papers
Peers
Comparison fields: 5 of 154
- Oncology 8.7k
- Immunology 5.8k
- Cancer Research 1.4k
- Pulmonary and Respiratory Medicine 2.7k
- Genetics 776
Countries citing papers authored by Marc S. Ernstoff
This map shows the geographic impact of Marc S. Ernstoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc S. Ernstoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc S. Ernstoff more than expected).
Fields of papers citing papers by Marc S. Ernstoff
This network shows the impact of papers produced by Marc S. Ernstoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc S. Ernstoff. The network helps show where Marc S. Ernstoff may publish in the future.
Co-authors
The 25 scholars most cited alongside Marc S. Ernstoff, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 299 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. Hit paper breakdown → | 1996 | 1501 |
| 2 | Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial Hit paper breakdown → | 2012 | 830 |
| 3 | High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190 Hit paper breakdown → | 2000 | 662 |
| 4 | High-Dose Interferon Alfa-2b Significantly Prolongs Relapse-Free and Overall Survival Compared With the GM2-KLH/QS-21 Vaccine in Patients With Resected Stage IIB-III Melanoma: Results of Intergroup Trial E1694/S9512/C509801 Hit paper breakdown → | 2001 | 657 |
| 5 | Arginase I–Producing Myeloid-Derived Suppressor Cells in Renal Cell Carcinoma Are a Subpopulation of Activated Granulocytes Hit paper breakdown → | 2009 | 635 |
| 6 | Randomized Phase III Trial of High-Dose Interleukin-2 Versus Subcutaneous Interleukin-2 and Interferon in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2004 | 602 |
| 7 | Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine in Patients With Metastatic Melanoma Hit paper breakdown → | 1999 | 543 |
| 8 | 2014 | 398 | |
| 9 | 2004 | 380 | |
| 10 | 1992 | 257 | |
| 11 | 1984 | 257 | |
| 12 | 2000 | 211 | |
| 13 | 2020 | 204 | |
| 14 | 2014 | 201 | |
| 15 | 2010 | 194 | |
| 16 | 1997 | 160 | |
| 17 | 2020 | 159 | |
| 18 | 2008 | 158 | |
| 19 | 2018 | 153 | |
| 20 | 2018 | 149 |
About Marc S. Ernstoff
Marc S. Ernstoff is a scholar working on Oncology, Immunology, Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research, having authored 299 papers that have together received 15.9k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (77 papers), Immunotherapy and Immune Responses (65 papers), CAR-T cell therapy research (43 papers), Renal cell carcinoma treatment (38 papers), Cutaneous Melanoma Detection and Management (27 papers), Cancer Genomics and Diagnostics (25 papers), Monoclonal and Polyclonal Antibodies Research (22 papers) and Immune Cell Function and Interaction (22 papers). The work is most often cited by research in Oncology (8.7k citations), Immunology (5.8k citations), Cancer Research (1.4k citations), Pulmonary and Respiratory Medicine (2.7k citations) and Genetics (776 citations). Marc S. Ernstoff has collaborated with scholars based in United States, United Kingdom and Canada. Frequent co-authors include John M. Kirkwood, Ronald H. Blum, Thomas J. Smith, Joseph G. Ibrahim, Vernon K. Sondak, Uma Rao, Michael B. Atkins, Kim Margolin, Jeffrey A. Sosman and Sanjiv S. Agarwala. Their work appears in journals such as Journal of Clinical Oncology, Journal for ImmunoTherapy of Cancer, Journal of Immunotherapy, Clinical Cancer Research and Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.